Prevalence and molecular characterization of fluoroquinolone- Resistant mycobacterium tuberculosis isolates in China

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 1, 2014, Pages 364-369

  Zhang, Zhijian ^a,b   Lu, Jie ^c   Wang, Yufeng ^b   Pang, Yu ^a,b   Zhao, Yanlin ^b  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHINA; GENE MUTATION; GENE SEQUENCE; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; CHINA; FLUOROQUINOLONES; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PREVALENCE;

EID: 84891541286     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01228-13     Document Type: Article

References (41)

1. World Health Organization. 2008. Anti-tuberculosis drug resistance in the world: Fourth global report. WHO/HTM/TB/2008.394. World Health Organization, Geneva, Switzerland.
2. Yumo HA, Mbanya D, Kuaban C, Neuhann F. 2011. Outcome assessment of a Global Fund grant for tuberculosis control at the district level in rural Cameroon. Int. J. Tuberc. Lung Dis. 15:352-357.
3. Ginsburg AS, Grosset JH, Bishai WR. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3:432-442. http://dx.doi.org/10 .1016/S1473-3099(03)00671-6.
4. Xu P, Li X, Zhao M, Gui X, DeRiemer K, Gagneux S, Mei J, Gao Q. 2009. Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. Antimicrob. Agents Chemother. 53:3170 - 3172. http://dx.doi.org/10.1128/AAC.00177-09.
5. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH, Hollm- Delgado MG, Keshavjee S, Deriemer K, Centis R, D'Ambrosio L, Lange C, Bauer M, Menzies D. 2013. Resistance to fluoroquinolones and second- line injectable drugs: Impact on MDR-TB outcomes. Eur. Respir. J. 42:156-168. http://dx.doi.org/10.1183/09031936.00134712.
6. Takiff H, Guerrero E. 2011. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob. Agents Chemother. 55: 5421-5429. http://dx.doi.org/10.1128/AAC.00695-11.
7. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, Cole ST, Jacobs WR, Jr, Telenti A. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38: 773-780. http://dx.doi.org/10.1128/AAC.38.4.773.
8. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. 2012. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J. Antimicrob. Chemother. 67:819-831. http://dx.doi.org/10. 1093/jac/dkr566.
9. Pantel A, Petrella S, Veziris N, Brossier F, Bastian S, Jarlier V, Mayer C, Aubry A. 2012. Extending the definition of the GyrB quinolone resistance- determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. Antimicrob. Agents Chemother. 56:1990-1996. http://dx.doi.org/10.1128/AAC.06272-11.
10. Zhao Y, Xu S, Wang L, Chin DP, Wang S, Jiang G, Xia H, Zhou Y, Li Q, Ou X, Pang Y, Song Y, Zhao B, Zhang H, He G, Guo J, Wang Y. 2012. National survey of drug-resistant tuberculosis in China. N. Engl. J. Med. 366:2161-2170. http://dx.doi.org/10.1056/NEJMoa1108789.
11. Mokrousov I, Jiao WW, Sun GZ, Liu JW, Valcheva V, Li M, Narvskaya O, Shen AD. 2006. Evolution of drug resistance in different sublineages of Mycobacterium tuberculosis Beijing genotype. Antimicrob. Agents Chemother. 50:2820-2823. http://dx.doi.org/10.1128/AAC.00324-06.
12. Zhu C, Zhang Y, Shen Y, Siu GK, Wu W, Qian X, Deng G, Xu Y, Lau R, Fan X, Zhang W, Lu H, Yam WC. 2012. Molecular characterization of fluoroquinolone- resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China. Diagn. Microbiol. Infect. Dis. 73:260-263. http: //dx.doi.org/10.1016/j. diagmicrobio.2012.03.025.
13. Zhou TL, Chen XJ, Zhou MM, Zhao YJ, Luo XH, Bao QY. 2011. Prevalence of plasmid-mediated quinolone resistance in Escherichia coli isolates in Wenzhou, Southern China, 2002-2008. Jpn. J. Infect. Dis. 64: 55-57.
14. Shi R, Zhang J, Li C, Kazumi Y, Sugawara I. 2006. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing highpressure liquid chromatography and DNA sequencing. J. Clin. Microbiol. 44:4566-4568. http://dx.doi.org/10.1128/JCM.01916-06.
15. Pang Y, Zhou Y, Zhao B, Liu G, Jiang G, Xia H, Song Y, Shang Y, Wang S, Zhao YL. 2012. Spoligotyping and drug resistance analysis of Mycobacterium tuberculosis strains from national survey in China. PLoS One 7:e32976. http://dx.doi.org/10.1371/journal.pone.0032976.
16. Pang Y, Zhou Y, Wang S, Lu J, Lu B, He G, Wang L, Zhao Y. 2011. A novel method based on high resolution melting (HRM) analysis for MIRU-VNTR genotyping of Mycobacterium tuberculosis. J. Microbiol. Methods 86:291-297. http://dx.doi.org/10.1016/j.mimet.2011.05.016.
17. Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y. 2013. Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 57:893-900. http://dx.doi.org/10.1128 /AAC.01024-12.
18. Nosova EY, Bukatina AA, Isaeva YD, Makarova MV, Galkina KY, Moroz AM. 2013. Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. J. Med. Microbiol. 62:108-113. http://dx.doi.org/10.1099/jmm. 0.046821-0.
19. World Health Organization. 2008. Policy guidance on drugsusceptibility testing (DST) of second-line antituberculosis drugs. WHO/ HTM/TB/2008.392. World Health Organization, Geneva, Switzerland.
20. Devasia R, Blackman A, Eden S, Li H, Maruri F, Shintani A, Alexander C, Kaiga A, Stratton CW, Warkentin J, Tang YW, Sterling TR. 2012. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J. Clin. Microbiol. 50:1390-1396. http://dx.doi.org/10.1128/JCM. 05286-11.
21. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry CE, 3, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544. http://dx.doi.org/10.1038/31159.
22. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van Soolingen D, Kuijper S, Bunschoten A, Molhuizen H, Shaw R, Goyal M, van Embden J. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35: 907-914.
23. Demay C, Liens B, Burguiere T, Hill V, Couvin D, Millet J, Mokrousov I, Sola C, Zozio T, Rastogi N. 2012. SITVITWEB-a publicly available international multimarker database for studying Mycobacterium tubercu- losis genetic diversity and molecular epidemiology. Infect. Genet. Evol. 12:755-766. http://dx.doi.org/10.1016/j.meegid.2012.02.004.
24. Huang HY, Tsai YS, Lee JJ, Chiang MC, Chen YH, Chiang CY, Lin NT, Tsai PJ. 2010. Mixed infection with Beijing and non-Beijing strains and drug resistance pattern of Mycobacterium tuberculosis. J. Clin. Microbiol. 48:4474-4480. http://dx.doi.org/10.1128/JCM.00930-10.
25. Lu B, Zhao P, Liu B, Dong H, Yu Q, Zhao X, Wan K. 2012. Genetic diversity of Mycobacterium tuberculosis isolates from Beijing, China assessed by spoligotyping, LSPs and VNTR profiles. BMC Infect. Dis. 12: 372. http://dx.doi.org/10.1186/1471-2334-12-372.
26. Roetzer A, Diel R, Kohl TA, Ruckert C, Nubel U, Blom J, Wirth T, Jaenicke S, Schuback S, Rusch-Gerdes S, Supply P, Kalinowski J, Niemann S. 2013. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: A longitudinal molecular epidemiological study. PLoS Med. 10:e1001387. http://dx.doi .org/10.1371/journal.pmed.1001387.
27. Huang TS, Kunin CM, Shin-Jung Lee S, Chen YS, Tu HZ, Liu YC. 2005. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J. Antimicrob. Chemother. 56:1058-1062. http://dx.doi.org/10.1093/jac/dki353.
28. Mokrousov I, Otten T, Manicheva O, Potapova Y, Vishnevsky B, Narvskaya O, Rastogi N. 2008. Molecular characterization of ofloxacinresistant Mycobacterium tuberculosis strains from Russia. Antimicrob. Agents Chemother. 52:2937-2939. http://dx.doi.org/10.1128/AAC.00036-08.
29. Sullivan EA, Kreiswirth BN, Palumbo L, Kapur V, Musser JM, Ebrahimzadeh A, Frieden TR. 1995. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 345:1148-1150. http://dx.doi.org /10.1016/S0140-6736(95)90980- X.
30. Lee AS, Tang LL, Lim IH, Wong SY. 2002. Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int. J. Infect. Dis. 6:48-51. http://dx.doi .org/10.1016/S1201-9712(02)90136-0.
31. Lacoma A, Garcia-Sierra N, Prat C, Maldonado J, Ruiz-Manzano J, Haba L, Gavin P, Samper S, Ausina V, Dominguez J. 2012. GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. J. Clin. Microbiol. 50:30-36. http://dx.doi.org/10.1128/JCM.05274-11.
32. Engström A, Morcillo N, Imperiale B, Hoffner SE, Jureen P. 2012. Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. J. Clin. Microbiol. 50:2026- 2033. http://dx.doi.org/10.1128/JCM.06664- 11.
33. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. 2011. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:2032-2041. http: //dx.doi.org/10.1128/AAC. 01550-10.
34. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. 2012. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: Functional genetic analysis of gyrA and gyrB mutations. PLoS One 7:e39754. http://dx doi.org/10.1371/journal.pone.0039754.
35. Pantel A, Petrella S, Matrat S, Brossier F, Bastian S, Reitter D, Jarlier V, Mayer C, Aubry A. 2011. DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 55:4524- 4529. http://dx.doi.org/10.1128/AAC.00707-11.
36. Louw GE, Warren RM, Gey van Pittius NC, McEvoy CR, Van Helden PD, Victor TC. 2009. A balancing act: efflux/influx in mycobacterial drug resistance. Antimicrob. Agents Chemother. 53:3181-3189. http://dx.doi .org/10.1128/AAC. 01577-08.
37. Riccardi G, Pasca MR, Buroni S. 2009. Mycobacterium tuberculosis: Drug resistance and future perspectives. Future Microbiol. 4:597-614. http://dx doi.org/10.2217/fmb.09.20.
38. Duong DA, Nguyen TH, Nguyen TN, Dai VH, Dang TM, Vo SK, Do DA, Nguyen VV, Nguyen HD, Dinh NS, Farrar J, Caws M. 2009. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob. Agents Chemother. 53:4835-4839. http://dx.doi.org/10.1128/AAC.00541-09.
39. Matrat S, Veziris N, Mayer C, Jarlier V, Truffot-Pernot C, Camuset J, Bouvet E, Cambau E, Aubry A. 2006. Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob. Agents Chemother. 50:4170-4173. http://dx.doi.org /10.1128/AAC.00944-06.
40. Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, da Silva PA. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53:4498-4500. http://dx.doi.org/10.1128/AAC.00287-09.
41. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, Hsueh PR, Yang PC. 2007. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: Associated genetic mutations and relationship to antimicrobial exposure. J. Antimicrob. Chemother. 59:860-865. http://dx.doi.org/10 .1093/jac/dkm061.